Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience
Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metasta...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2017-12, Vol.23 (8), p.615-619 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 619 |
|---|---|
| container_issue | 8 |
| container_start_page | 615 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 23 |
| creator | Ramudo-Cela, Luis Balea-Filgueiras, Jesús Vizoso-Hermida, José Ramón Martín-Herranz, Isabel |
| description | Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment. |
| doi_str_mv | 10.1177/1078155216674354 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_1078155216674354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155216674354</sage_id><sourcerecordid>10.1177_1078155216674354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-4b4e65a42d6d961aef0532d63ff9700b1eeca1e71e67fb0df6f00b6075fd08c83</originalsourceid><addsrcrecordid>eNp1UMtKAzEUDaLYWt27kvxANJlHMl1K0SoUXKjgbsgkNzbFmQxJBjo7f8Pf80tMqboQhAv3cR5wD0LnjF4yJsQVo6JiZZkxzkWRl8UBmrJCCELn2cthmhNMdvgEnYSwoZRWIquO0SQTosx5Vk1R-xgHPWJnsJIBwm6QjfUygncdYG2Dcl203SCjdR3WA-DoUm2tsnHEtsO9B6LW0Lq4Bi_7EUuTxJjhEaT_fP8IGLY9eAudglN0ZORbgLPvPkPPtzdPizuyeljeL65XROW5iKRoCuClLDLN9ZwzCYaWeVpyY-aC0oYBKMlAMODCNFQbbtKVU1EaTStV5TNE977KuxA8mLr3tpV-rBmtd8nVf5NLkou9pB-aFvSv4CeqRCB7QpCvUG_c4Lv0wv-GXzYJeRo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Ramudo-Cela, Luis ; Balea-Filgueiras, Jesús ; Vizoso-Hermida, José Ramón ; Martín-Herranz, Isabel</creator><creatorcontrib>Ramudo-Cela, Luis ; Balea-Filgueiras, Jesús ; Vizoso-Hermida, José Ramón ; Martín-Herranz, Isabel</creatorcontrib><description>Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155216674354</identifier><identifier>PMID: 27753628</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Abiraterone Acetate - adverse effects ; Abiraterone Acetate - therapeutic use ; Aged, 80 and over ; Androstenes - adverse effects ; Androstenes - therapeutic use ; Disease Progression ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms, Castration-Resistant - blood ; Prostatic Neoplasms, Castration-Resistant - diagnosis ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Safety-Based Drug Withdrawals - trends ; Taxoids - adverse effects ; Taxoids - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Journal of oncology pharmacy practice, 2017-12, Vol.23 (8), p.615-619</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-4b4e65a42d6d961aef0532d63ff9700b1eeca1e71e67fb0df6f00b6075fd08c83</citedby><cites>FETCH-LOGICAL-c337t-4b4e65a42d6d961aef0532d63ff9700b1eeca1e71e67fb0df6f00b6075fd08c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1078155216674354$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1078155216674354$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27753628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramudo-Cela, Luis</creatorcontrib><creatorcontrib>Balea-Filgueiras, Jesús</creatorcontrib><creatorcontrib>Vizoso-Hermida, José Ramón</creatorcontrib><creatorcontrib>Martín-Herranz, Isabel</creatorcontrib><title>Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment.</description><subject>Abiraterone Acetate - adverse effects</subject><subject>Abiraterone Acetate - therapeutic use</subject><subject>Aged, 80 and over</subject><subject>Androstenes - adverse effects</subject><subject>Androstenes - therapeutic use</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prostatic Neoplasms, Castration-Resistant - blood</subject><subject>Prostatic Neoplasms, Castration-Resistant - diagnosis</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Safety-Based Drug Withdrawals - trends</subject><subject>Taxoids - adverse effects</subject><subject>Taxoids - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UMtKAzEUDaLYWt27kvxANJlHMl1K0SoUXKjgbsgkNzbFmQxJBjo7f8Pf80tMqboQhAv3cR5wD0LnjF4yJsQVo6JiZZkxzkWRl8UBmrJCCELn2cthmhNMdvgEnYSwoZRWIquO0SQTosx5Vk1R-xgHPWJnsJIBwm6QjfUygncdYG2Dcl203SCjdR3WA-DoUm2tsnHEtsO9B6LW0Lq4Bi_7EUuTxJjhEaT_fP8IGLY9eAudglN0ZORbgLPvPkPPtzdPizuyeljeL65XROW5iKRoCuClLDLN9ZwzCYaWeVpyY-aC0oYBKMlAMODCNFQbbtKVU1EaTStV5TNE977KuxA8mLr3tpV-rBmtd8nVf5NLkou9pB-aFvSv4CeqRCB7QpCvUG_c4Lv0wv-GXzYJeRo</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Ramudo-Cela, Luis</creator><creator>Balea-Filgueiras, Jesús</creator><creator>Vizoso-Hermida, José Ramón</creator><creator>Martín-Herranz, Isabel</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201712</creationdate><title>Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience</title><author>Ramudo-Cela, Luis ; Balea-Filgueiras, Jesús ; Vizoso-Hermida, José Ramón ; Martín-Herranz, Isabel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-4b4e65a42d6d961aef0532d63ff9700b1eeca1e71e67fb0df6f00b6075fd08c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abiraterone Acetate - adverse effects</topic><topic>Abiraterone Acetate - therapeutic use</topic><topic>Aged, 80 and over</topic><topic>Androstenes - adverse effects</topic><topic>Androstenes - therapeutic use</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prostatic Neoplasms, Castration-Resistant - blood</topic><topic>Prostatic Neoplasms, Castration-Resistant - diagnosis</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Safety-Based Drug Withdrawals - trends</topic><topic>Taxoids - adverse effects</topic><topic>Taxoids - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramudo-Cela, Luis</creatorcontrib><creatorcontrib>Balea-Filgueiras, Jesús</creatorcontrib><creatorcontrib>Vizoso-Hermida, José Ramón</creatorcontrib><creatorcontrib>Martín-Herranz, Isabel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramudo-Cela, Luis</au><au>Balea-Filgueiras, Jesús</au><au>Vizoso-Hermida, José Ramón</au><au>Martín-Herranz, Isabel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2017-12</date><risdate>2017</risdate><volume>23</volume><issue>8</issue><spage>615</spage><epage>619</epage><pages>615-619</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>27753628</pmid><doi>10.1177/1078155216674354</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2017-12, Vol.23 (8), p.615-619 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_crossref_primary_10_1177_1078155216674354 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Abiraterone Acetate - adverse effects Abiraterone Acetate - therapeutic use Aged, 80 and over Androstenes - adverse effects Androstenes - therapeutic use Disease Progression Humans Male Middle Aged Prostatic Neoplasms, Castration-Resistant - blood Prostatic Neoplasms, Castration-Resistant - diagnosis Prostatic Neoplasms, Castration-Resistant - drug therapy Safety-Based Drug Withdrawals - trends Taxoids - adverse effects Taxoids - therapeutic use Time Factors Treatment Outcome |
| title | Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T11%3A38%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Study%20of%20cases%20of%20abiraterone%20discontinuation%20due%20to%20toxicity%20in%20pre-chemotherapy%20after%201%20year%E2%80%99s%20experience&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Ramudo-Cela,%20Luis&rft.date=2017-12&rft.volume=23&rft.issue=8&rft.spage=615&rft.epage=619&rft.pages=615-619&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155216674354&rft_dat=%3Csage_cross%3E10.1177_1078155216674354%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27753628&rft_sage_id=10.1177_1078155216674354&rfr_iscdi=true |